Symposium:
86. Friendly Fire—Immunotherapies and Infectious Diseases
Thursday, October 27, 2016: 2:00 PM-3:30 PM
Room: Theater A & B

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • compare the mechanism of action and infectious disease risk profiles of classic and novel immunomodulators used in rheumatologic and autoimmune diseases
  • distinguish the mechanism of action of novel immunotherapies for treatment of cancer and their associated risks of autoimmunity and infection
  • examine different CAR-T cell based immunotherapies for treatment of cancer and certain infectious diseases

Target Audience: Academicians, Clinicians, Epidemiologists, Fellows, Infectious diseases physicians, Investigators, Members-in-training, Pharmacists, Researchers, Scientists

Tracks: Adult ID, Epidemiology and Infection Control, Investigative ID

Moderator:  Francisco M. Marty, MD, FIDSA, Brigham and Women's Hospital

Presentations:
2:00 PM
811
Immunomodulators for Rheumatologic Diseases
Kevin L. Winthrop, MD, MPH

2:25 PM
Q&A
2:55 PM
Q&A
3:25 PM
Q&A

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.5 knowledge-based contact hours 0.15 of pharmacy CE

ACPE Number: 0221-9999-16-234-L01-P

Disclosures:

F. M. Marty, Alexion: Scientific Advisor , Consulting fee
Ansun: Investigator , Research support
Astellas: Consultant and Investigator , Consulting fee and Research support
Basilea: Conference speaker , Speaker honorarium
Chimerix: Consultant and Investigator , Consulting fee and Research support
Gilead: Consultant and Investigator , Consulting fee and Research support
GlaxoSmithKline: Consultant and Investigator , Consulting fee and Research grant
LFB, S.A.: Consultant , Consulting fee
Merck: Consultant and Investigator , Consulting fee and Research support
Shire: Consultant and Investigator , Consulting fee and Research support
WHISCON: Investigator , Research support
Pfizer: Course speaker , Speaker honorarium
Fate Therapeutics: Scientific Advisor , Consulting fee

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.